Familial Adenomatous Polyposis (FAP) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Familial Adenomatous Polyposis Emerging Therapy and TPP Insights

Thelansis’s “Familial Adenomatous Polyposis (FAP) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Familial Adenomatous Polyposis (FAP) Overview

Familial adenomatous polyposis (FAP) is an inherited tumor-predisposition syndrome, usually caused by a germline APC mutation, in which hundreds to thousands of colorectal adenomas can develop from a young age, creating an extremely high lifetime risk of colorectal cancer without appropriate management. For decades, care has centered on intensive endoscopic surveillance, polyp removal, and risk-reducing colorectal surgery, which substantially reduces cancer risk but can introduce lifelong changes in bowel function and other surgical morbidity. Desmoid tumors and upper-GI polyposis add further long-term management challenges. Pharmacologic chemoprevention remains investigational: the pivotal Phase 3 trial of sulindac plus eflornithine did not significantly reduce its primary disease-progression endpoint, although a later post-hoc analysis suggested potential benefit in delaying lower-GI progression and surgery. For healthcare leaders, FAP represents an important cancer-interception opportunity, with research focused on whether safe, durable therapies can reduce polyp burden and ultimately lessen the need for major prophylactic surgery.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)